NR ATLK
AU Kuhn,F.; Pürro,M.; Schmid,J.; Roller,M.; Lohmann,C.; Oesch,B.; Raeber,A.J.
TI Detection of PrPsc by FACS using the prion specific antibody 15B3
QU International Conference - Prion 2005: Between fundamentals and society's needs - 19.10.-21.10.2005, Congress Center Düsseldorf - Poster Session: Diagnosis DIA-48
PT Konferenz-Poster
AB
Recently, variant Creutzfeldt-Jakob disease (vCJD) was diagnosed in two people having received blood from preclinical vCJD patients. Even though the possibility of infection in the recipient could have been due to past dietary exposure to the BSE agent, these incidences illustrate the urgent need for the development of TSE ante mortem diagnostic tests. The detection of PrPsc in blood of TSE infected animals and humans has been hampered by the low levels and the lack of proteinase resistance of PrPsc in blood (Yakovleva et al., 2004) which require enrichment of the analyte PrPsc before the detection step. The prion specific mono-clonal antibody 15B3 has been shown to specifically recognize the disease-associated form of PrP and to be capable of detecting PrPsc in brain homogenates without the need of pro-teinase K digestion. Recently, it has been reported that the antibody 15B3 is capable of pre-cipitating protease-sensitive forms of PrPsc in a transgenic mouse model of Gerstmann Sträussler Scheinker syndrome suggesting that this monoclonal antibody might be a valuable tool for the development of a blood based TSE test (Nazor et al., 2005). Here we show detection of PrPsc from brain, serum and white blood cells by fluorescent activated cell sorting (FACS) using the monoclonal antibody 15B3.
References:
Yakovleva O, Janiak A, McKenzie C, McShane L, Brown P, Cervenakova L.
Effect of protease treatment on plasma infectivity in variant Creutzfeldt-Jakob disease mice.
Transfusion. 2004; 44:1700-5
Karah E. Nazor, Franziska Kuhn, Tanya Seward, Mike Green, Daniel Zwald, Mario Pürro, Jaqueline Schmid, Karin Biffiger, Aisling M. Power, Bruno Oesch, Alex J. Raeber and Glenn C. Telling Immunodetection of disease-associated mutant PrP which accelerates disease in GSS transgenic mice. EMBO J 2005; in press.
IN Die Autoren meinen, dem im Blut befindlichen PrPsc fehle die Resistenz gegen die Proteinase K. Daraus leiten sie die Notwendigkeit ab, einen neuen TSE-Bluttest zu entwickeln, der ohne Proteasebehandlung auskommt. Sie empfehlen dafür ihren alten PRPsc-spezifischen Antikörper 15B3, den sie selbst aber in ihren kommerziellen TSE-Tests nicht einsetzen.
AD F.Kuhn, M.Pürro, J.Schmid, M.Roller, C.Lohmann, B.Oesch, A.J.Raeber, Prionics AG, Switzerland
SP englisch
PO Deutschland